Vivos Therapeutics closes SOD Sciences stake and 50% test interest for preferred stock
Vivos Therapeutics closed on October 16, 2026 its acquisition of an 11% fully diluted stake in SOD Sciences and a 50% co-ownership interest in SOD's pseudohypoxia early-warning test, paying with 12,000 shares of newly created Series C Convertible Preferred Stock and no cash. The preferred converts at $0.15 per share into up to 80,000,000 common shares, which could dilute existing holders, and the company expects the deal to raise stockholders' equity by more than $10 million, which it says may restore compliance with a Nasdaq minimum.
Key points
- Closed October 16, 2026: 3,057,879 SOD common shares (at least 11% fully diluted) plus a 50% interest in the test and related IP, for 12,000 Series C Preferred with a $12,000,000 aggregate stated value; no cash paid.
- Series C converts at $0.15 per share into up to 80,000,000 common shares; until stockholder approval, conversions are capped at 6,718,517 shares, against 33,609,393 common shares outstanding before the signing.
- Vivos expects stockholders' equity to rise by more than $10 million, citing $10,380,000 of expected additional equity, and believes this restores compliance with Nasdaq's $2.5 million stockholders' equity requirement, subject to Nasdaq revi
- Commercial benefits depend on definitive agreements with AHA, which is in bankruptcy proceedings, and Cleveland Clinic Weston, neither of which had been executed as of the filing.
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 19, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.